SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

被引：0

作者：

Curioni-Fontecedro, A. ^{[1
]}

Holer, L. ^{[2
]}

Frueh, M. ^{[3
]}

Weindler, S. ^{[4
]}

Konig, D. ^{[5
]}

Addeo, A. ^{[6
]}

Britschgi, C. ^{[7
]}

Rigutto, A. ^{[8
,9
]}

Waibel, C. ^{[10
]}

Bettini, A. ^{[11
]}

Cerciello, F. W. F. ^{[12
]}

Hiltbrunner, S. ^{[9
,13
]}

Nguyen, D. L. ^{[14
]}

Zellweger, C. ^{[15
]}

Musilova, J. ^{[16
]}

Von Moos, R. A. F. ^{[17
]}

Joerger, M. ^{[18
]}

机构：

[1] Univ Zurich Hosp, Dept Oncol, Cantonal Hosp Fribourg, Fribourg, Switzerland

[2] SAKK Swiss Grp Clin Canc Res, Bern, Switzerland

[3] Kantonsspital St Gallen, Dept Oncol, St Gallen, Switzerland

[4] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland

[5] Univ Basel Hosp, Dept Med Oncol, Basel, Switzerland

[6] HUG Hop Univ Geneve, Dept Oncol, Geneva, Switzerland

[7] USZ Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

[8] Univ Zurich, Fac Sci & Med, Dept Med Surg Specialties, Zurich, Switzerland

[9] Univ Fribourg, Fribourg, Switzerland

[10] Kantonsspital Baden, Med Oncol, Baden, Switzerland

[11] HFR Hop Cantonal, Med Oncol, Fribourg, Switzerland

[12] Univ Klin Med Onkol, Dept Med Oncol, Inselspital, Bern, Switzerland

[13] Univ Zurich Hosp, Fac Sci & Med, Zurich, Switzerland

[14] Stadtsp Zurich Triemli, Dept Radiol & Nucl Med, Zurich, Switzerland

[15] USZ Univ Hosp Zurich, Dept Radiol, Inst Diagnost & Intervent Radiol, Zurich, Switzerland

[16] SAKK Swiss Grp Clin Canc Res, Dept Stat, Bern, Switzerland

[17] KSGR Kantonsspital Graubunden, Dept Hematol Oncol, Chur, Switzerland

[18] Kantonsspital St Gallen, Med Oncol & Hematol Dept, St Gallen, Switzerland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1412P

引用

页数：2

共 50 条

[41] Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)
Kosmidis, PA
Kalofonos, C
Syrigos, K
Skarlos, D
Fountzilas, G
Nicolaides, C
Bafaloukos, D
Samantas, E
Bakogiannis, C
Dimopoulos, AM
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 621S - 621S
[42] A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM101-015 trial.
Fusi, Alberto
Gupta, Avinash
Lorigan, Paul
Smith, Peter L.
Bowles, Mike
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[43] A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast
de la Cruz, Luis
Sanchez-Margalet, Victor
Berraondo, Pedro
Benito, Sara
Jose Escudero, Ma
Caballero, Rosalia
Carrasco, Eva
Galluzzi, Lorenzo
Rojo, Federico
CANCER RESEARCH, 2018, 78 (04)
[44] Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
Michael, Michael
White, Shane C.
Abdi, Ehtesham
Nott, Louise
Clingan, Phillip
Zimet, Allan
Button, Peter
Gregory, Daniel
Solomon, Benjamin
Dobrovic, Alexander
Do, Hongdo
Clarke, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (01) : 4 - 14
[45] Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
Susen Burock
Severin Daum
Ulrich Keilholz
Konrad Neumann
Wolfgang Walther
Ulrike Stein
BMC Cancer, 18
[46] Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
Burock, Susen
Daum, Severin
Keilholz, Ulrich
Neumann, Konrad
Walther, Wolfgang
Stein, Ulrike
BMC CANCER, 2018, 18
[47] Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)
Shibayama, Hirohiko
Kawaguchi, Tatsuya
Kuroda, Junya
Nakamae, Hirohisa
Matsumura, Itaru
Miyamoto, Toshihiro
Ishikawa, Jun
Kamimura, Tomohiko
Fukushima, Kentaro
Imamura, Yutaka
Eto, Tetsuya
Sunami, Kazutaka
Shimokawa, Mototsugu
Akashi, Koichi
Kanakura, Yuzuru
BLOOD, 2016, 128 (22)
[48] Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial
Pastorelli, Davide
Fabricio, Aline S. C.
Giovanis, Petros
D'Ippolito, Simona
Fiduccia, Pasquale
Solda, Caterina
Buda, Andrea
Sperti, Cosimo
Bardini, Romeo
Da Dalt, Gianfranco
Rainato, Giulia
Gion, Massimo
Ursini, Fulvio
PHARMACOLOGICAL RESEARCH, 2018, 132 : 72 - 79
[49] A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.
Montillo, Marco
Rossi, Davide
Zucca, Emanuele
Frustaci, Anna Maria
Pileri, Stefano
Cavalli, Franco
Tedeschi, Alessandra
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKFS633/DANTE trial, a trial of AIO in collaboration with SAKK
Al-Batran, Salah-Eddin
Lorenzen, Sylvie
Thuss-Patience, Peter C.
Homann, Nils
Schenk, Michael
Lindig, Udo
Heuer, Vera
Kretzschmar, Albrecht
Goekkurt, Eray
Haag, Georg Martin
Riera-Knorrenschild, Jorge
Bolling, Claus
Hofheinz, Ralf-Dieter
Angermeier, Stefan
Ettrich, Thomas Jens
Siebenhuener, Alexander Reinhard
Kopp, Christina
Pauligk, Claudia
Goetze, Thorsten Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →